Effective Pain Palliation in Fibromyalgia Syndrome Patients with Botulinum Toxin Type-A: Case Series of 25

REFERENCES

• Wolfe F, Smythe H A., Yunus M B., Bennett R M., Bombardier C, Goldenberg D L., Tugwell P, Campbell S M., Abeles M, Clark P, Fam A G., Farber S J., Fiechtner J J., Franklin C M., Gatter R A., Hamaty D, Lessard J, Lichtbroun A S., Masi A T., McCain G A., Reynolds W J., Romano T J., Russell I J., Sheon R P. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum 1990; 33: 160–172
   PubMed Web of Science ®Google Scholar
• Wolfe F, Ross K, Anderson J, Russell I J., Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1990; 33: 160–172
   PubMed Web of Science ®Google Scholar
• Plesh O, Wolfe F, Lane N. The relationship between fibromyalgia and temporomandibular disorders: prevalence and symptom severity. J Rheumatol 1996; 23: 1948–1952
   PubMed Web of Science ®Google Scholar
• Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Advances in Experimental Medicine & Biology 1996; 398: 373–379
   PubMedGoogle Scholar
• Wolfe F. Post-traumatic fibromyalgia: a case report narrated by the patient. Arthritis Care Res 1994; 7: 161–165
   PubMedGoogle Scholar
• Waylonis G W., Perkins R H. Post-traumatic fibromyalgia. A long-term follow-up. Amer J Phys Med Rehabil 1994; 73: 403–412
   PubMed Web of Science ®Google Scholar
• Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. Increased rates of fibromyalgia after cervical spine injury: a controlled study of 161 cases of traumatic injury. Arthritis Rheum 1997; 40: 446–452
   PubMed Web of Science ®Google Scholar
• Wolfe F, the Vancouver Fibromyalgia Consensus Group. Special report: the fibromyalgia syndrome: a consensus report on fibromyalgia and disability. J Rheumatol 1996; 23: 534–539
   PubMed Web of Science ®Google Scholar
• Russell I J. Fibromyalgia syndrome Muscle pain: Understanding Its Nature, Diagnosis, and Treatment, S Mense, D G. Simons. Lippincott Williams & Wilkins, Baltimore 2001; 289–237
   Google Scholar
• White K P., Speechley M, Harth M, Ostbye T. The London fibromyalgia epidemiology study: direct health care costs of fibromyalgia syndrome in London, Canada. J Rheumatol 1995; 26: 885–889
   Google Scholar
• Jain A K., Carruthers B M., van de Sande M I., Barron S R., Donaldson C CS, Dunne J V., Gingrich E, Heffez D S., Leung F YK, Malone D G., Romano T J., Russell I J., Saul D, Seibel D G. Fibromyalgia syndrome: Canadian clinical working case definition, diagnostic and treatment protocols-A Consensus document. J Musculoske Pain 2003; 11: 103–107
   Google Scholar
• Jain A K., Carruthers B M., van de Sande M I., Barron S R., Donaldson C CS, Dunne J V., Gingrich E, Heffez D S., Leung F YK, Malone D G., Romano T J., Russell I J., Saul D, Seibel D G. Fibromyalgia syndrome: Canadian clinical working case definition, diagnostic and treatment protocols-A Consensus document. J Musculoskel Pain 2003; 11, 41
   Google Scholar
• Simons D G. Muscular pain syndrome. Advances in Pain Research and Therapy, J R. Fricton, E Awad. Raven Press, New York 1990; Vol 17: 1–41
   Google Scholar
• Gerwin R D. A study of 96 subjects examined both for fibromyalgia and myofascial pain. J Musculoske Pain 1995; 3(Suppl 1), 121
   Google Scholar
• Hong C Z., Hsueh T C. Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 1996; 77: 1161–1166
   PubMed Web of Science ®Google Scholar
• Hong C Z., Simons D G. Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil 1998; 79: 863–872
   PubMed Web of Science ®Google Scholar
• Klein A W., Glogau R G. Botulinum toxin: beyond cosmesis. Arch Dermatol 2000; 136: 539–541
   PubMedGoogle Scholar
• Dolly J O. Molecular characteristics and mechanisms underlying the therapeutic effectiveness of Botulinum Toxins Canadian Botulinum Toxin Conference. 2004, April
   Google Scholar
• Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004; 20: 981–990
   PubMed Web of Science ®Google Scholar
• Childers M K., Kornegay J N., Aoki R, Otaviani L, Bogan D J., Petroski G. Evaluating motor end-plate-targeted injections of botulinum toxin type A in a canine model. Muscle Nerve 1998; 21: 653–655
   PubMed Web of Science ®Google Scholar
• Palik N J., Seo K I., Kim M W., Han T R., Eun H C. The impacts of refrigerator storage on the potency of botulinum toxin type A in humans Abstract for Poster Session II, AAEM annual meeting. 2000
   Google Scholar
• Hudson J I., Goldenberg D L., Pope H G., Jr., Keck P E., Jr., Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Amer J Med 1999; 92: 363–367
   Google Scholar
• Lapossy E, Maleitzke R, Hrycaj P, Mennet W, Muller W. The frequency of transition of chronic low back pain to fibromyalgia. Scand J Rheumatol 1995; 24: 29–33
   PubMed Web of Science ®Google Scholar
• Huppe A, Brockow T, Raspe H. Chronic widespread pain and tender points in low back pain: a population-based study. Z Rheumatol 2004; 63: 76–83
   PubMedGoogle Scholar
• Ko G D., Berbrayer D, Lo J K. Fibromyalgia patients with headache effectively treated with botulinum toxin type A: a case series. Arch Phys Med Rehabil 2001; 82, 1321
   Google Scholar
• Ko G D., Berbrayer D. Fibromyalgia and low back pain treated with Botox: case reports. Poster presented at the Canadian Association of Physical Medicine and Rehabilitation meeting, Halifax, Nova Scotia. June 15. 2001
   Google Scholar
• Boisset-Pioro M H., Esdaile J M., Fitzcharles M A. Sexual and physical abuse in women with fibromyalgia syndrome. Arthritis Rheum 1995; 38: 235–241
   PubMed Web of Science ®Google Scholar
• Taylor M L., Trotter D R., Csuka M E. The prevalence of sexual abuse in women with fibromyalgia. Arthritis Rheum 1995; 38: 229–234
   PubMed Web of Science ®Google Scholar
• Kraj N J., Norregaard J, Larsen J K., Danneskiold-Samsoe B. A blinded controlled evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured by standardized psychometric interview scales. Acta Psychiatrica Scandinavica 1994; 89: 370–375
   PubMedGoogle Scholar
• Yunus M B., Aldag J C. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. Brit Med J 1996; 312: 1336–1339
   PubMedGoogle Scholar
• Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med 1975; 37: 341–351
   PubMed Web of Science ®Google Scholar
• Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. Increased rates of fibromyalgia after cervical spine injury: a controlled study of 161 cases of traumatic injury. Arthritis Rheum 1997; 40: 446–452
   PubMed Web of Science ®Google Scholar
• Rivera J, DeDiego A, Trinchet M, Monforte A G. Fibromyalgia-associated Hepatitis C virus infection. Br J Rheumatol 1997; 36: 981–985
   PubMedGoogle Scholar
• Mannerkorpi K, Svantesson U, Broberg C. Relationship between performance-based tests and patient's ratings of activity limitations, self-efficacy, and pain in Fibromyalgia. Arch Phys Med Rehabil 2006; 87: 259–264
   PubMed Web of Science ®Google Scholar
• Paulson G W., Gill W. Botulinum toxin is unsatisfactory therapy for fibromyalgia. Movement Disorders 1996; 11, 459
   PubMedGoogle Scholar
• Cheshire W P., Abashian S W., Mann J D. Botuli-num toxin in the treatment of myofascial pain syndrome. Pain 1994; 59: 65–69
   PubMed Web of Science ®Google Scholar
• Alo K M., Yland M J., Kramer D L., Charnov J H., Redko V. Botulinum toxin in the treatment of myofascial pain. Pain Clinic 1997; 10: 107–116
   Google Scholar
• Childers M K., Wilson D J., Galate J F., Smith B K. Treatment of painful muscle syndromes with botulinum toxin: a review. J Back Musculoskel Rehabil 1998; 10: 89–96
   Web of Science ®Google Scholar
• Lang A M. A pilot study of botulinum toxin type A, administered using a novel injection technique, for the treatment of myofascial pain. Am J Pain Manage 2000; 10: 108–112
   Google Scholar
• Barwood S, Baillieu C, Boyd R, Brereton K, Low J, Nattrass G, Graham H K. Analgesic effects of botuli-num toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol 2000; 42: 116–121
   PubMed Web of Science ®Google Scholar
• Porta M. A comparative trial of botulinum toxin A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000; 85: 101–5
   PubMed Web of Science ®Google Scholar
• Graboski C L., Gray S, Burnham R S. Botulinum toxin type A versus Bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomized double blind crossover study. Poster 156 at the American Academy of Physical Medicine and Rehabilitation's 66th Annual assembly, Philadelphia. 2005
   Google Scholar
• Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 2000; 40: 445–450
   PubMed Web of Science ®Google Scholar
• Relja M A., Korsic M. Treatment of tension-type headache by injections of botulinum toxin type A: double-blind placebo-controlled study. Neurology 1999; 52(6 Suppl 2)A203, P03.035
   Google Scholar
• Freund B J., Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache 2000; 40: 231–236
   PubMed Web of Science ®Google Scholar
• Gobel H, Heinze A, Heinze-Kuhn K, Auster-mann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2000; 91: 195–199
   Google Scholar
• Foster L, Clapp L, Erickson M, Jabarri B. Botuli-num toxin A and chronic low back pain: a randomized, double blind study. Neurology 2000; 56: 1290–1293
   Google Scholar
• Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of Substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochemical Pharmacology 2000; 59: 1403–1406
   PubMed Web of Science ®Google Scholar
• Van den Bergh P, De Beukelaer M, Deconinck N. Effect of muscle denervation on the expression of substance P in the ventral raphe-spinal pathway of the rat. Brain Res 1996; 707: 206–212
   PubMedGoogle Scholar
• Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000; 44: 106–109
   PubMed Web of Science ®Google Scholar
• Durham P L., Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004; 44: 35–43
   PubMed Web of Science ®Google Scholar
• Morris J L., Jobling P, Gibbins I L. Differential inhibition by botulinum neuro-toxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001; 281: 2124–2132
   Web of Science ®Google Scholar
• Humm A M., Pabst C, Lauterburg T, Burgunder J M. Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin. Exp Neurol 2000; 161: 361–372
   PubMedGoogle Scholar
• Cui M, Aoki K R. Botulinum toxin A reduces inflammatory pain in the rat formalin model. Cephalalgia 2000; 20, 414
   Google Scholar
• Cui M, Li Z, You S, Khanijou S, Aoki R. Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of peripheral and central nociceptive processing. Arch Pharmacol 2002; 365: R17
   Web of Science ®Google Scholar
• Cui M, Khanijou S, Rubino J, Aoki K R. Subcutaneous Botulinum Toxin A reduces formalin-induced glutamate release in the rat paw. Pain 2004; 107: 125–133
   PubMed Web of Science ®Google Scholar
• Cui M, Li Z, You S, Khanijou S, Aoki K R. Subcutaneou BoNT-A (3 dpi) inhibits formalin-evoked Fos expression in the superficial dorsal horn (Laminae I & II). IASP poster #834.P104. Aug 20. 2002
   Google Scholar
• Ko G D., Finkelstein I, Hum A. Botulinum toxin-A alleviates trigeminal and post-herpetic neuralgia facial pain. Clin Invest Med 2004; 27, 204
   Google Scholar
• Freund B, Schwartz M. Subcutaneous Botulinum toxin Type A in the treatment of postherpetic neuralgia: a case series of 24 patients. Arch Phys Med Rehabil 2004; 85: E37–38
   Google Scholar
• Salemi S, Rethage J, Wollina U, Michel B A., Gay R E., Gay S. Detection of interleukin lbeta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 2003; 30: 146–150
   PubMed Web of Science ®Google Scholar
• Crofford L J., Rowbotham M C., Mease P J., Russell I J., Dworkin R H., Corbin A E., Young J P., LaMoreaux L K., Martin S A., Sharma U, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264–73
   PubMed Web of Science ®Google Scholar
• McLain D. An open label dose finding trial of Tizanidine [Zanaflex™]for treatment of fibromyalgia. J Musculoskel Pain 2002; 10: 7–18
   Web of Science ®Google Scholar
• Bennett R M., Schein J, Kosinski M R., Hewitt D J., Jordan D M., Rosenthal N R. Impact of fibromyalgia pain on health-related quality of life before and after treatment with Tramadol/Acetaminophen. Arthritis Rheum 2005; 53: 519–27
   PubMed Web of Science ®Google Scholar
• Ko G D., Wine W. Chronic pain and cannabinoids: a survey of current fibromyalgia treatment approaches together with an overview and case studies of a new “old” treatment approach. Practical Pain Management 2005; 5(4)28–39
   Google Scholar
• Russo E. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuroendocrinology Letters. 2004; 25(1–2)31–39, Feb-Apr
   PubMed Web of Science ®Google Scholar
• Erbguth F J. Pain in Cervical Dystonia. Botulinum toxin in painful diseases. Pain and Headache, W H. Jost, 2003; 14: 54–70
   Google Scholar
• Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain 2003; 4: 159–165
   PubMedGoogle Scholar
• Busch A, Schachter C L., Peloso P M., Bombardier C. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev (3) 2002, CD003786
   Google Scholar
• Baumgartner E, Finckh A, Cedraschi C, Vischer T L. A six year prospective study of a cohort of patients with fibromyalgia. Ann Rheum Dis 2002; 61: 644–645
   PubMed Web of Science ®Google Scholar
• Yunus M B., Arslan S, Aldag J C. Relationship between fibromyalgia features and smoking. Scand J Rheumatol 2002; 31: 301–305
   PubMed Web of Science ®Google Scholar
• Fitzcharles M A., Costa D D., Poyhia R. A study of standard care in fibromyalgia syndrome: a favorable outcome. J Rheumatol 2003; 30: 154–159
   PubMed Web of Science ®Google Scholar
• Turk D C., Okifuji A, Sinclair J D., Starz T W. Interdisciplinary treatment for fibromyalgia syndrome: clinical and statistical significance. Arthritis Care Res 1998; 11: 186–195
   PubMed Web of Science ®Google Scholar
• King S J., Wessel J, Bhambhani Y, Sholter D, Maksymowych W. The effects of exercise and education, individually or combined, in women with fibro-myalgia. J Rheumatol 2002; 29: 2620–2627
   PubMed Web of Science ®Google Scholar
• Gustafsson M, Ekholm J, Broman L. Effects of a multiprofessional rehabilitation programme for patients with fibromyalgia syndrome. J Rehabil Med 2002; 119–127
   PubMedGoogle Scholar
• Wigers S H. Fibromyalgia outcome: the predictive values of symptom duration, physical activity, disability pension, and critical life events: a 4.5 year prospective study. J Psychosom Res 1996; 41: 235–243
   PubMed Web of Science ®Google Scholar